ABSTRACT
Soluble interleukin-2 receptor alpha [sIL-2Ralpha is a well-known indicator of T-cell activation noted to be increasing in nasopharyngeal cancer. The aims of this study were to evaluate the importance of the use of this marker in nasopharyngeal carcinoma. Our prospective study interested 45 patients [35M/10F] with a mean age of 49 years [15 to 78], presenting a nasopharyngeal carcinoma histologically confirmed and 61 healthy controls. A blood sample was collected from each patient before any treatment, as well as controls to measure sIL-2Ralpha by immunoenzymatic assay. According to the disease status after a period of follow-up ranging from three to 22 months [median 12 months], patients were divided into two groups: The remission group [n = 28] represented those with favourable evolution and a second group of 15 patients with unfavourable evolution [2 death, 4 cases of persistent primary disease and 9 patients with distance metastasis]. 2 patients were lost to follow-up. serum sIL-2Ralpha levels were significantly higher in patients vs healthy controls [p < 0.0001]. The serum levels correlated with the stage T of NPC [p = 0.01]. Patients having a favourable evolution have lower sIL-2Ralpha levels before treatment vs those with unfavourable evolution without statistical difference. Measurement of serum sIL-2Ralpha provides a good estimation of the nasopharyngeal tumor burden. The usefulness of this marker as a parameter to predict prognosis in NPC should be examined further